Synthetic antibodies designed on natural sequence landscapes.
about
Deep sequencing in library selection projects: what insight does it bring?Next generation sequencing: new tools in immunology and hematologyHigh-Throughput Sequencing-Based Immune Repertoire Study during Infectious DiseaseSynthetic approach to the generation of antibody diversityIBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CAHighly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies.Rep-Seq: uncovering the immunological repertoire through next-generation sequencing.The selection performance of an antibody library displayed on filamentous phage coat proteins p9, p3 and truncated p3Construction of a rationally designed antibody platform for sequencing-assisted selection.Frontier of therapeutic antibody discovery: The challenges and how to face them.ProxiMAX randomization: a new technology for non-degenerate saturation mutagenesis of contiguous codonsThe application of next generation sequencing to the understanding of antibody repertoires.Predominant structural configuration of natural antibody repertoires enables potent antibody responses against protein antigensHigh-Throughput Ligand Discovery Reveals a Sitewise Gradient of Diversity in Broadly Evolved Hydrophilic Fibronectin DomainsA Novel Human scFv Library with Non-Combinatorial Synthetic CDR Diversity.Optimizing antibody expression by using the naturally occurring framework diversity in a live bacterial antibody display systemUnderstanding differences between synthetic and natural antibodies can help improve antibody engineering.Assessing kinetic and epitopic diversity across orthogonal monoclonal antibody generation platformsNaLi-H1: A universal synthetic library of humanized nanobodies providing highly functional antibodies and intrabodies.Generation and analyses of human synthetic antibody libraries and their application for protein microarrays.High-Resolution Phenotypic Landscape of the RNA Polymerase II Trigger Loop.Construction of a scFv Library with Synthetic, Non-combinatorial CDR Diversity.Natural and man-made V-gene repertoires for antibody discovery.A Combination of Structural and Empirical Analyses Delineates the Key Contacts Mediating Stability and Affinity Increases in an Optimized Biotherapeutic Single-chain Fv (scFv).Efficient affinity maturation of antibody variable domains requires co-selection of compensatory mutations to maintain thermodynamic stability.Candidate antibody-based therapeutics against HIV-1.Immunoglobulin domains in Escherichia coli and other enterobacteria: from pathogenesis to applications in antibody technologies.Analysis of 5518 unique, productively rearranged human VH3-23*01 gene sequences reveals CDR-H3 length-dependent usage of the IGHD2 gene family.A Diverse Repertoire of Human Immunoglobulin Variable Genes in a Chicken B Cell Line is Generated by Both Gene Conversion and Somatic Hypermutation.Optimization of a β-sheet-cap for long loop closure.Facile Affinity Maturation of Antibody Variable Domains Using Natural Diversity Mutagenesis.Generation, Diversity Determination, and Application to Antibody Selection of a Human Naïve Fab Library.Prediction of delayed retention of antibodies in hydrophobic interaction chromatography from sequence using machine learning.Phage display and selection of lanthipeptides on the carboxy-terminus of the gene-3 minor coat protein.Integrating high-throughput screening and sequencing for monoclonal antibody discovery and engineering.Rational library design by functional CDR resampling.Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies.High-throughput antibody engineering in mammalian cells by CRISPR/Cas9-mediated homology-directed mutagenesis
P2860
Q26785457-2BF4FDA7-12EC-4920-A1E1-73B1C7A18FC7Q27025231-AC9ABB14-5348-4D05-B1E3-C42C83BE25CBQ28068214-25EB1DD3-6C6A-4755-A9E3-96C57A2CD431Q28086872-C4861AAE-4912-4D0C-80B5-A3D9320E052AQ28660580-AA59D842-7ED3-4BD0-9C84-2410496BF95EQ33721106-0339C7E2-44AA-4C5B-8D04-D74D7A3A64A6Q34063790-AAB5BB8D-AECC-46EA-B717-D37B2F4220D1Q34252187-9633E8CC-D887-4040-B74B-E80930C21565Q34445071-678877D2-486B-433A-8638-882239B2D437Q34527769-35DC51C4-A62F-4785-96E9-240DA45C6ACCQ34995423-E1F8DFF5-0C27-442F-9CD1-14F696908588Q34996112-CC5A7E98-5934-4D8A-BACB-DC0B4705D5A4Q35707409-74F9A5BB-582F-4606-8E89-E31B198252BCQ35780298-C0BE6E79-38D0-4BBE-9428-105AA454D680Q35814423-B097998A-6BA4-4430-8580-D08FBDAE0886Q35859635-60A5DD50-E96D-45C6-A2FE-93A2CA0214B1Q35864868-C69C808A-804B-470C-A117-02148E614175Q35864980-C7951E9D-6EBB-4136-BA95-61C5506E9ED6Q36081897-895B4AE8-3D2F-4FF5-A691-65024AEA2A27Q36122012-014C0592-F2DA-4AF6-B3FD-159D2D4D7324Q36206756-ED3FDCE2-7508-4510-A6B8-1B96FC8EF038Q36296217-64F37CD3-F104-4317-8FB1-FA2D505E2FD8Q36401413-50A3D4F6-FD11-49FF-9DD2-660B9C574019Q36466175-47788B2B-4D7D-41E2-9A09-9DF8F51023E8Q37724050-2F3A3E6E-5645-4822-B6BA-F2ADBE15B427Q37998496-6025386E-3EB3-4850-880B-370C6B133961Q38020872-33F0C261-B807-450F-B627-F27DC6F36626Q38804075-3A3A8F33-C9DB-4E82-8E9D-CDDDB69CB7E1Q38889822-DCB1C565-62B2-4906-AC14-3D6230FC64D2Q39324214-14E5D51A-3C6C-400A-A4E3-FB411F3442B9Q41472386-92BBF8AB-661C-4C77-8894-BE1E5F6DBC89Q42375944-4624971F-9D16-453A-B060-3227D652A7DDQ45945330-79E4EDFB-DE46-4462-8F88-B9C9A4A4212DQ47134907-52F619F5-3454-4637-8F8C-F60CAD132861Q47684836-2ED9C648-A8FA-497B-A397-67BEB8CC09A9Q49839193-6FD72211-BA55-406D-BA3D-B3CAA230BC9EQ49951608-A9E0A386-8011-4DF3-8AB6-EB50F24BC2D2Q56888745-2379AC07-221A-4EE2-B34E-0A1C43452803
P2860
Synthetic antibodies designed on natural sequence landscapes.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Synthetic antibodies designed on natural sequence landscapes.
@ast
Synthetic antibodies designed on natural sequence landscapes.
@en
type
label
Synthetic antibodies designed on natural sequence landscapes.
@ast
Synthetic antibodies designed on natural sequence landscapes.
@en
prefLabel
Synthetic antibodies designed on natural sequence landscapes.
@ast
Synthetic antibodies designed on natural sequence landscapes.
@en
P2093
P1476
Synthetic antibodies designed on natural sequence landscapes.
@en
P2093
Arvind Rajpal
Dilduz Telman
Guido Cappuccilli
Jacob Glanville
Jan Van den Brulle
Jaume Pons
Kevin Lindquist
Markus Fuhrmann
P356
10.1016/J.JMB.2011.07.018
P407
P50
P577
2011-07-23T00:00:00Z